Skip to main content
Top
Published in:

Open Access 09-05-2024 | Human Immunodeficiency Virus | Review

Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review

Authors: Wendy J. Boschloo, Berend J. van Welzen

Published in: Infectious Diseases and Therapy | Issue 6/2024

Login to get access

Abstract

The human immunodeficiency virus type 2 (HIV-2) is a particular subtype of HIV, which is endemic in West Africa and is characterized by a more indolent course than HIV-1. As people living with HIV-2 (PWH-2) are at risk for the development of acquired immunodeficiency syndrome and can transmit the virus, antiretroviral therapy is usually indicated. However, the optimal treatment of HIV-2 is unknown and historically the protease inhibitors (PIs) were a regular part of therapy. Nowadays, the use of integrase strand transfer inhibitors (INSTIs) in HIV-2 is increasing but the evidence supporting this approach is limited. In this narrative review, we outline the clinical data on the use of INSTI-containing antiretroviral therapy in HIV-2. We found that in the setting of treatment-naïve PWH-2, the use of INSTIs is successful, but also noted large heterogeneity in reported outcomes and that most cohorts are small with limited follow-up time. There is a lack of studies comparing the efficacy of INSTIs to other first-line options. For treatment-experienced PWH-2, the efficacy of INSTI is highly variable.
Literature
1.
go back to reference Marlink R, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994;265(5178):1587–90.PubMedCrossRef Marlink R, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994;265(5178):1587–90.PubMedCrossRef
2.
go back to reference MacNeil A, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol. 2007;81(10):5325–30.PubMedPubMedCentralCrossRef MacNeil A, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol. 2007;81(10):5325–30.PubMedPubMedCentralCrossRef
3.
go back to reference van der Loeff MF, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology. 2010;7:46.PubMedPubMedCentralCrossRef van der Loeff MF, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology. 2010;7:46.PubMedPubMedCentralCrossRef
4.
go back to reference Martinez-Steele E, et al. Is HIV-2-induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS. 2007;21(3):317–24.PubMedCrossRef Martinez-Steele E, et al. Is HIV-2-induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS. 2007;21(3):317–24.PubMedCrossRef
5.
go back to reference Jaffar S, et al. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ. 2004;82(6):462–9.PubMedPubMedCentral Jaffar S, et al. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ. 2004;82(6):462–9.PubMedPubMedCentral
8.
go back to reference Witvrouw M, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9(1):57–65.PubMedCrossRef Witvrouw M, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9(1):57–65.PubMedCrossRef
9.
go back to reference Ren J, et al. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA. 2002;99(22):14410–5.PubMedPubMedCentralCrossRef Ren J, et al. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA. 2002;99(22):14410–5.PubMedPubMedCentralCrossRef
10.
go back to reference Desbois D, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother. 2008;52(4):1545–8.PubMedPubMedCentralCrossRef Desbois D, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother. 2008;52(4):1545–8.PubMedPubMedCentralCrossRef
11.
go back to reference Gilleece Y, et al. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med. 2010;11(10):611–9.PubMedCrossRef Gilleece Y, et al. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med. 2010;11(10):611–9.PubMedCrossRef
13.
go back to reference Reeves I, et al. British HIV Association guidelines for the management of HIV-2 2021. HIV Med. 2021;22(Suppl 4):1–29.PubMedCrossRef Reeves I, et al. British HIV Association guidelines for the management of HIV-2 2021. HIV Med. 2021;22(Suppl 4):1–29.PubMedCrossRef
14.
go back to reference Ambrosioni J, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023. Ambrosioni J, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023.
15.
go back to reference Roquebert B, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62(5):914–20.PubMedCrossRef Roquebert B, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62(5):914–20.PubMedCrossRef
16.
go back to reference Andreatta K, Miller MD, White KL. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. J Acquir Immune Defic Syndr. 2013;62(4):367–74.PubMedCrossRef Andreatta K, Miller MD, White KL. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. J Acquir Immune Defic Syndr. 2013;62(4):367–74.PubMedCrossRef
17.
go back to reference Smith RA, et al. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS. 2011;25(18):2235–41.PubMedCrossRef Smith RA, et al. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS. 2011;25(18):2235–41.PubMedCrossRef
18.
go back to reference Shimura K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82(2):764–74.PubMedCrossRef Shimura K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82(2):764–74.PubMedCrossRef
19.
go back to reference Charpentier C, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS. 2010;24(17):2753–5.PubMedCrossRef Charpentier C, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS. 2010;24(17):2753–5.PubMedCrossRef
21.
go back to reference Smith RA, et al. Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants. Antimicrob Agents Chemother. 2019;63(5). Smith RA, et al. Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants. Antimicrob Agents Chemother. 2019;63(5).
22.
go back to reference Le Hingrat Q, et al. A new mechanism of resistance of human immunodeficiency virus type 2 to integrase inhibitors: a 5-amino-acid insertion in the integrase C-terminal domain. Clin Infect Dis. 2019;69(4):657–67.PubMedCrossRef Le Hingrat Q, et al. A new mechanism of resistance of human immunodeficiency virus type 2 to integrase inhibitors: a 5-amino-acid insertion in the integrase C-terminal domain. Clin Infect Dis. 2019;69(4):657–67.PubMedCrossRef
23.
go back to reference Tsiang M, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086–97.PubMedPubMedCentralCrossRef Tsiang M, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086–97.PubMedPubMedCentralCrossRef
24.
go back to reference Smith RA, et al. In vitro antiviral activity of cabotegravir against HIV-2. Antimicrob Agents Chemother, 2018;62(10). Smith RA, et al. In vitro antiviral activity of cabotegravir against HIV-2. Antimicrob Agents Chemother, 2018;62(10).
25.
go back to reference Damond F, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS. 2008;22(5):665–6.PubMedCrossRef Damond F, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS. 2008;22(5):665–6.PubMedCrossRef
26.
go back to reference Garrett N, et al. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS. 2008;22(9):1091–2.PubMedCrossRef Garrett N, et al. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS. 2008;22(9):1091–2.PubMedCrossRef
27.
go back to reference Roquebert B, et al. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS. 2008;22(15):2045–6.PubMedCrossRef Roquebert B, et al. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS. 2008;22(15):2045–6.PubMedCrossRef
28.
go back to reference Salgado M, et al. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol. 2009;46(2):173–5.PubMedCrossRef Salgado M, et al. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol. 2009;46(2):173–5.PubMedCrossRef
29.
go back to reference Armstrong-James D, et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res. 2010;86(2):224–6.PubMedCrossRef Armstrong-James D, et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res. 2010;86(2):224–6.PubMedCrossRef
30.
go back to reference Burger DM, et al. Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis. AIDS. 2010;24(2):328–30.PubMedCrossRef Burger DM, et al. Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis. AIDS. 2010;24(2):328–30.PubMedCrossRef
31.
go back to reference Francisci D, et al. HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen? Clin Drug Investig. 2011;31(5):345–9.PubMedCrossRef Francisci D, et al. HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen? Clin Drug Investig. 2011;31(5):345–9.PubMedCrossRef
32.
go back to reference Wandeler G, Furrer H, Rauch A. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. AIDS. 2011;25(18):2306–8.PubMedCrossRef Wandeler G, Furrer H, Rauch A. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. AIDS. 2011;25(18):2306–8.PubMedCrossRef
33.
go back to reference Peterson K, et al. The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series. Antivir Ther. 2012;17(6):1097–100.PubMedCrossRef Peterson K, et al. The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series. Antivir Ther. 2012;17(6):1097–100.PubMedCrossRef
34.
go back to reference Zheng Y, et al. Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naïve HIV-2-infected patient. AIDS. 2014;28(15):2329–31.PubMedCrossRef Zheng Y, et al. Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naïve HIV-2-infected patient. AIDS. 2014;28(15):2329–31.PubMedCrossRef
35.
go back to reference Delory T, et al. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: a case-series experience. J Med Virol. 2016;88(7):1204–10.PubMedCrossRef Delory T, et al. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: a case-series experience. J Med Virol. 2016;88(7):1204–10.PubMedCrossRef
36.
go back to reference Treviño A, et al. Dolutegravir for the treatment of HIV-2 infection. J Clin Virol. 2015;64:12–5.PubMedCrossRef Treviño A, et al. Dolutegravir for the treatment of HIV-2 infection. J Clin Virol. 2015;64:12–5.PubMedCrossRef
37.
go back to reference Ceia F, et al. Human immunodeficiency virus (HIV) 2 superinfection in a patient receiving antiretroviral therapy with longstanding HIV-1 viral load suppression. Open Forum Infect Dis. 2019;6(4):ofz63.CrossRef Ceia F, et al. Human immunodeficiency virus (HIV) 2 superinfection in a patient receiving antiretroviral therapy with longstanding HIV-1 viral load suppression. Open Forum Infect Dis. 2019;6(4):ofz63.CrossRef
38.
go back to reference Tchounga BK, et al. Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa. PLoS One. 2020;15(8): e0236642.PubMedPubMedCentralCrossRef Tchounga BK, et al. Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa. PLoS One. 2020;15(8): e0236642.PubMedPubMedCentralCrossRef
39.
40.
go back to reference Doroana MC, Piñeiro MF, Fonseca P, Oliveira J, Mansinho K, Horta A, Teófilo E, Aguas M, Germano I. Faria D (2010) Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients. J Int AIDS Soc. 2010;13(54):P34.PubMedCentral Doroana MC, Piñeiro MF, Fonseca P, Oliveira J, Mansinho K, Horta A, Teófilo E, Aguas M, Germano I. Faria D (2010) Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients. J Int AIDS Soc. 2010;13(54):P34.PubMedCentral
41.
go back to reference Charpentier C, et al. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother. 2011;55(3):1293–5.PubMedCrossRef Charpentier C, et al. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother. 2011;55(3):1293–5.PubMedCrossRef
42.
go back to reference Descamps D, et al. Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French named patient program. Clin Infect Dis. 2015;60(10):1521–7.PubMed Descamps D, et al. Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French named patient program. Clin Infect Dis. 2015;60(10):1521–7.PubMed
43.
go back to reference Sequeira F, et al. Integrase strand transfer inhibitors in the treatment of HIV-2 infection: report of 39 patients. J Int AIDS Soc. 2016;19:98. Sequeira F, et al. Integrase strand transfer inhibitors in the treatment of HIV-2 infection: report of 39 patients. J Int AIDS Soc. 2016;19:98.
44.
go back to reference Ba S, et al. A trial of a single-tablet regimen of Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for the initial treatment of human immunodeficiency virus type 2 infection in a resource-limited setting: 48-week results from Senegal, West Africa. Clin Infect Dis. 2018;67(10):1588–94.PubMedPubMedCentralCrossRef Ba S, et al. A trial of a single-tablet regimen of Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for the initial treatment of human immunodeficiency virus type 2 infection in a resource-limited setting: 48-week results from Senegal, West Africa. Clin Infect Dis. 2018;67(10):1588–94.PubMedPubMedCentralCrossRef
45.
go back to reference Matheron S, et al. First-line raltegravir/emtricitabine/tenofovir combination in human immunodeficiency virus type 2 (HIV-2) infection: a phase 2, noncomparative trial (ANRS 159 HIV-2). Clin Infect Dis. 2018;67(8):1161–7.PubMedPubMedCentralCrossRef Matheron S, et al. First-line raltegravir/emtricitabine/tenofovir combination in human immunodeficiency virus type 2 (HIV-2) infection: a phase 2, noncomparative trial (ANRS 159 HIV-2). Clin Infect Dis. 2018;67(8):1161–7.PubMedPubMedCentralCrossRef
46.
go back to reference Requena S, et al. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. J Antimicrob Chemother. 2019;74(5):1357–62.PubMedCrossRef Requena S, et al. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. J Antimicrob Chemother. 2019;74(5):1357–62.PubMedCrossRef
47.
go back to reference Pujari S, et al. Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: retrospective observational study from Western India. J Antimicrob Chemother. 2020;75(7):1950–4.PubMedCrossRef Pujari S, et al. Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: retrospective observational study from Western India. J Antimicrob Chemother. 2020;75(7):1950–4.PubMedCrossRef
48.
go back to reference Joly VA, et al. Immuno-virological and clinical follow-up of HIV-2 patients receiving BIC/FTC/TAF. Top Antiv Med. 2023;31(2):212. Joly VA, et al. Immuno-virological and clinical follow-up of HIV-2 patients receiving BIC/FTC/TAF. Top Antiv Med. 2023;31(2):212.
49.
go back to reference Pacheco P, et al. Safety and efficacy of triple therapy with dolutegravir plus 2 nucleoside reverse transcriptase inhibitors in treatment-naive human immunodeficiency virus type 2 patients: results from a 48-week phase 2 study. Clin Infect Dis. 2023;77(5):740–8.PubMedCrossRef Pacheco P, et al. Safety and efficacy of triple therapy with dolutegravir plus 2 nucleoside reverse transcriptase inhibitors in treatment-naive human immunodeficiency virus type 2 patients: results from a 48-week phase 2 study. Clin Infect Dis. 2023;77(5):740–8.PubMedCrossRef
Metadata
Title
Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review
Authors
Wendy J. Boschloo
Berend J. van Welzen
Publication date
09-05-2024
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 6/2024
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-024-00982-7

Other articles of this Issue 6/2024

Infectious Diseases and Therapy 6/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare